Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Core Viewpoint - Atea Pharmaceuticals, Inc. is set to host a live conference call on March 6, 2025, to report its financial results for Q4 and the full year of 2024, along with a business update [1]. Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapies for serious viral diseases [3]. - The company utilizes a proprietary nucleos(t)ide prodrug platform to develop novel product candidates targeting single-stranded RNA viruses, which are significant causes of serious viral infections [3]. - Atea's lead program focuses on the development of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, aimed at treating Hepatitis C Virus (HCV) [3]. Conference Call Details - Participants can register for the live conference call and access the audio webcast through Atea's Investor Relations website [2]. - The audio webcast will be archived on the company's website for at least 90 days following the event [2].